Press releases or official announcements from pharmaceutical companies

EU to Approve U.S. Self-Amplifying RNA COVID-19 Vaccine Following Japan's Approval of ARCT-154 Self-Replicating mRNA

Dec 17, 2024, 02:23 PM

The European Union is set to approve a new self-amplifying RNA-based COVID-19 vaccine developed by a U.S. company. This follows Japan's recent approval of a similar self-replicating mRNA vaccine, ARCT-154, which allows the mRNA to replicate within cells. The advancements in mRNA technology, including the use of lipid nanoparticles (LNPs), are aimed at enhancing vaccine efficacy and targeting specific diseases. Researchers have also made progress in developing modified LNPs capable of crossing the blood-brain barrier, potentially enabling targeted therapies for brain and inflammatory diseases.